Phospho-BIK (T33) Antibody

What is BIK and what is the significance of its phosphorylation at threonine 33?

BIK (Bcl-2-interacting killer, also known as NBK, BIP1, or BP4) is an 18 kDa pro-apoptotic protein that functions as a death accelerator in programmed cell death pathways. BIK is encoded by the BIK gene (Gene ID: 638) and shares a critical BH3 domain with other death-promoting proteins such as BAX and BAK .

BIK primarily functions by interacting with cellular and viral survival-promoting proteins, including Bcl-2, Bcl-X(L), BHRF1, and the Epstein-Barr virus protein E1B 19k. These interactions enhance programmed cell death by neutralizing anti-apoptotic proteins . Importantly, BIK does not interact with BAX, suggesting it operates through a distinct mechanism compared to other BH3-only proteins .

Phosphorylation at threonine 33 (T33) is a critical post-translational modification that regulates BIK activity. This specific phosphorylation site serves as a molecular switch that can alter BIK's interactions with its binding partners and influence its pro-apoptotic function. Detecting this phosphorylation event is crucial for understanding BIK regulation in various cellular contexts.

What cellular localization patterns are expected when studying phosphorylated BIK?

Phosphorylated BIK exhibits specific subcellular localization patterns that are important for its function. According to current research, BIK is primarily located in:

• Endomembrane system as a single-pass membrane protein

• Mitochondrion membrane as a single-pass membrane protein

• Around the nuclear envelope

• Within cytoplasmic membranes

When performing immunohistochemistry or immunofluorescence studies, researchers should expect to observe these localization patterns. Alterations in this distribution may indicate changes in BIK function or regulation in experimental or pathological conditions.

What are the key technical specifications for commercially available Phospho-BIK (T33) antibodies?

The following table summarizes the technical specifications of various commercially available Phospho-BIK (T33) antibodies based on manufacturer data:

These antibodies are specifically designed to detect endogenous levels of BIK only when phosphorylated at threonine 33, making them valuable tools for studying this post-translational modification .

What experimental applications are most suitable for Phospho-BIK (T33) antibodies?

Phospho-BIK (T33) antibodies have been validated for several experimental applications:

• Western Blot (WB): The primary application for detecting phosphorylated BIK in protein lysates. Recommended dilutions range from 1:500 to 1:3000, depending on the manufacturer .

• Immunohistochemistry (IHC): Used for detecting phosphorylated BIK in fixed tissue sections. Most manufacturers recommend dilutions between 1:50 and 1:300 .

• ELISA: Some antibodies have been validated for ELISA applications with recommended dilutions of approximately 1:10000 .

• Blocking/Control Experiments: Phospho-BIK (T33) peptides are available for antibody validation and blocking experiments to confirm specificity .

When planning experiments, researchers should optimize antibody dilutions for their specific experimental systems and include appropriate controls to validate specificity.

What are the recommended protocols for using Phospho-BIK (T33) antibody in Western blot applications?

Western Blot Protocol for Phospho-BIK (T33) Detection:

• Sample Preparation:

  • Extract proteins from cells or tissues using a lysis buffer containing phosphatase inhibitors

  • Quantify protein concentrations using Bradford or BCA assay

  • Prepare samples in Laemmli buffer with reducing agent

• Gel Electrophoresis:

  • Load 20-30 μg protein per lane

  • Use 12-15% SDS-PAGE (higher percentage recommended for better resolution of low MW proteins)

  • Include molecular weight markers spanning 10-25 kDa range

• Transfer and Blocking:

  • Transfer proteins to PVDF membrane (recommended over nitrocellulose for phosphoproteins)

  • Block with 5% BSA in TBST (not milk, which contains phosphoproteins)

• Primary Antibody Incubation:

  • Dilute Phospho-BIK (T33) antibody in 5% BSA/TBST (1:500-1:3000)

  • Incubate overnight at 4°C with gentle agitation

• Detection:

  • Use appropriate HRP-conjugated secondary antibody

  • Develop using enhanced chemiluminescence

  • Expected band size: approximately 18 kDa

• Controls:

  • Include phosphatase-treated samples as negative controls

  • Consider using Phospho-BIK (T33) blocking peptide to confirm specificity

What are the optimal procedures for immunohistochemistry using Phospho-BIK (T33) antibody?

Immunohistochemistry Protocol for Phospho-BIK (T33) Detection:

• Tissue Preparation:

  • Fix tissues in 4% paraformaldehyde

  • Dehydrate, clear, and embed in paraffin

  • Cut 4-6 μm sections onto charged slides

• Antigen Retrieval:

  • Deparaffinize and rehydrate sections

  • Perform heat-induced epitope retrieval (citrate buffer pH 6.0 or EDTA buffer pH 9.0)

  • Allow slides to cool to room temperature

• Blocking and Primary Antibody:

  • Block endogenous peroxidase activity with 3% H₂O₂

  • Block non-specific binding with 5% normal serum

  • Apply Phospho-BIK (T33) antibody at 1:50-1:100 dilution

  • Incubate overnight at 4°C in a humidified chamber

• Detection:

  • Use appropriate detection system (ABC or polymer-based)

  • Develop with DAB substrate

  • Counterstain with hematoxylin

  • Expected localization: cytoplasmic membranes, perinuclear region, and mitochondrial patterns

• Controls:

  • Include sections treated with non-phospho-specific BIK antibody

  • Consider using Phospho-BIK (T33) blocking peptide in parallel sections

How can researchers verify the specificity of Phospho-BIK (T33) antibody in experimental systems?

Verifying antibody specificity is critical for obtaining reliable results. For Phospho-BIK (T33) antibody, consider these validation approaches:

• Peptide Competition Assay:

  • Pre-incubate the antibody with synthetic Phospho-BIK (T33) peptide

  • Run parallel Western blots or IHC with blocked and unblocked antibody

  • Specific binding should be absent in assays performed with neutralized antibody

• Phosphatase Treatment Control:

  • Treat one set of samples with lambda phosphatase

  • Compare signal intensity between treated and untreated samples

  • Signal should be diminished or absent in phosphatase-treated samples

• siRNA or CRISPR Knockout:

  • Generate BIK knockdown or knockout samples

  • Compare antibody reactivity between wild-type and knockout samples

  • Signal should be absent in properly validated knockdown/knockout samples

• Induced Phosphorylation:

  • Treat cells with agents known to induce BIK phosphorylation

  • Compare signal in treated versus untreated samples

  • Signal should increase in conditions that enhance phosphorylation

What are the key considerations for studying BIK phosphorylation in apoptosis research?

When investigating BIK phosphorylation in apoptosis pathways, researchers should consider:

• Temporal Dynamics:

  • BIK phosphorylation may be transient during apoptosis

  • Design time-course experiments to capture phosphorylation events

  • Consider using proteasome inhibitors to prevent degradation of phosphorylated proteins

• Interaction Analysis:

  • Investigate how T33 phosphorylation affects BIK's interaction with anti-apoptotic proteins

  • Consider co-immunoprecipitation experiments using Phospho-BIK (T33) antibody

  • Analyze interactions with specific partners (Bcl-2, Bcl-X(L), etc.)

• Cell-Type Specificity:

  • BIK expression and phosphorylation patterns vary across cell types

  • Include multiple cell lines or primary cells in comparative studies

  • Correlate phosphorylation with functional outcomes (apoptosis rates)

• Pathway Integration:

  • Consider upstream kinases responsible for T33 phosphorylation

  • Investigate downstream effects on mitochondrial membrane permeability

  • Analyze crosstalk with other apoptotic pathways

What are common challenges when working with Phospho-BIK (T33) antibody and how can they be addressed?

Researchers may encounter several challenges when working with Phospho-BIK (T33) antibodies:

• Low Signal Intensity:

  • Increase antibody concentration or incubation time

  • Enhance signal with amplification systems

  • Ensure samples are prepared with phosphatase inhibitors

  • Optimize antigen retrieval methods for IHC

• High Background:

  • Increase blocking time or blocking agent concentration

  • Optimize antibody dilution

  • Use more stringent washing conditions

  • For Western blot, consider 5% BSA instead of milk for blocking

• Non-specific Bands:

  • Validate with peptide competition assay

  • Increase gel percentage for better resolution

  • Optimize sample preparation to reduce protein degradation

  • Consider using gradient gels for improved separation

• Inconsistent Results:

  • Ensure proper antibody storage (-20°C, avoid freeze-thaw cycles)

  • Aliquot antibody to minimize freeze-thaw cycles

  • Standardize sample collection and processing

  • Include positive controls in each experiment

How should researchers evaluate batch-to-batch consistency of Phospho-BIK (T33) antibodies?

Batch-to-batch variability can significantly impact experimental results. To ensure consistency:

• Reference Batch Comparison:

  • Compare new batches to previously validated batches

  • Perform parallel Western blots or ELISAs with both batches

  • Quantify and compare signal intensities

• Quality Control Testing:

  • Request lot-specific validation data from manufacturers

  • Perform specificity testing with each new lot

  • Consider using peptide competition assays to verify specificity

• Quantitative Assessment:

  • Use dilution series to generate standard curves

  • Compare EC50 values between batches

  • Document performance characteristics for future reference

• Documentation:

  • Record lot numbers and performance characteristics

  • Maintain a laboratory database of antibody performance

  • Consider freezing aliquots of well-performing batches as reference standards

What emerging applications exist for Phospho-BIK (T33) antibodies in cancer research?

Phospho-BIK (T33) antibodies are becoming increasingly important in cancer research:

• Biomarker Development:

  • Investigate Phospho-BIK (T33) as a potential prognostic marker

  • Correlate phosphorylation levels with treatment response

  • Develop tissue microarray studies across cancer types

• Therapeutic Response Monitoring:

  • Analyze changes in BIK phosphorylation following chemotherapy

  • Investigate BIK phosphorylation in acquired resistance mechanisms

  • Develop companion diagnostics for therapies targeting apoptotic pathways

• Targeted Therapy Development:

  • Identify compounds that modulate BIK phosphorylation

  • Develop peptide mimetics based on BIK phosphorylation sites

  • Screen for molecules that enhance BIK-mediated apoptosis

• Combination Therapy Rationales:

  • Investigate how BIK phosphorylation affects response to established therapies

  • Develop rational combination approaches targeting BIK and related pathways

  • Identify synthetic lethal interactions involving BIK phosphorylation

How can researchers integrate Phospho-BIK (T33) antibody-based assays with other methodologies?

Integrating multiple methodologies can provide more comprehensive insights:

• Multi-omics Approaches:

  • Combine antibody-based detection with phosphoproteomics

  • Correlate BIK phosphorylation with transcriptomic changes

  • Integrate with metabolomic data to understand metabolic consequences

• High-Content Imaging:

  • Develop multiplexed immunofluorescence panels including Phospho-BIK (T33)

  • Quantify subcellular localization changes upon phosphorylation

  • Correlate with mitochondrial morphology and function

• Single-Cell Analysis:

  • Adapt Phospho-BIK (T33) detection for flow cytometry or mass cytometry

  • Investigate cell-to-cell variability in BIK phosphorylation

  • Correlate with other apoptotic markers at single-cell level

• Structural Biology Integration:

  • Use antibody-based findings to inform structural studies

  • Investigate how phosphorylation alters BIK protein conformation

  • Develop structure-based therapeutic approaches